CymaBay Therapeutics and Other Major Stocks Surge on Monday

U.S. equities were in a state of incongruity as the Nasdaq Composite remained relatively unchanged on Monday.

Today, CymaBay Therapeutics saw a remarkable escalation in pre-market trading, with shares experiencing a significant upturn.

Gilead Sciences has struck an accord to procure CymaBay Therapeutics at $32.50 per share, amounting to a total equity value of $4.3 billion.

Consequently, CymaBay Therapeutics observed an impressive surge of 24.5% at $31.99 on Monday.

The bullish climate extended beyond CymaBay Therapeutics, as several other prominent stocks recorded substantial gains during today’s session, marking a significant momentum shift in the market.

• ContextLogic Inc. with the ticker WISH ascended by 40.2% to $6.31 following the company’s announcement of selling a major chunk of its operational assets and liabilities to Qoo10 for approximately $173 million in cash.
• Iris Energy Limited represented by the ticker IREN surged 18% to $7.01.
• Viavi Solutions Inc. identified by the ticker VIAV witnessed a rise of 14.1% to $10.16. A profound endorsement from Stifel analyst Ruben Roy, who upgraded Viavi Solutions from Hold to Buy and heightened the price target from $10 to $13, amplified the company’s rally.
• The E.W. Scripps Company with the ticker SSP surged 14% to $6.69.
• IGM Biosciences, Inc. symbolized by the ticker IGMS gained 13.7% to $16.50. This remarkable ascent came on the heels of a recent upgrade by RBC Capital, who advanced the stock from Sector Perform to Outperform and raised the price target from $9 to $21.

Now Read This: Jim Cramer Says This Construction Giant Is ‘So Good’ And ‘Goes Higher’